Monomethylarsonous acid inhibited endogenous cholesterol biosynthesis in human skin fibroblasts

Toxicology and Applied Pharmacology

Volumn 277, Issue 1, 2014, Pages 21-29

  Guo, Lei ^a   Xiao, Yongsheng ^a   Wang, Yinsheng ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

De novo cholesterol biosynthesis; FASP; Monomethylarsonous acid; Quantitative proteomics; SILAC

Indexed keywords

ARSENIC; CHOLESTEROL; MESSENGER RNA; MONOMETHYLARSONOUS ACID; PROTEOME; SELENOPROTEIN; STABLE ISOTOPE; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ARTICLE; CELL CULTURE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; CULTURE MEDIUM; CYTOTOXICITY; DOWN REGULATION; GENETIC SELECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; ISOTOPE LABELING; LIQUID CHROMATOGRAPHY; PROTEIN SYNTHESIS; PROTEOMICS; REAL TIME POLYMERASE CHAIN REACTION; SKIN FIBROBLAST; TANDEM MASS SPECTROMETRY;

DE NOVO CHOLESTEROL BIOSYNTHESIS; FASP; MONOMETHYLARSONOUS ACID; QUANTITATIVE PROTEOMICS; SILAC;

CELL CULTURE TECHNIQUES; CELL LINE; CELL SURVIVAL; CHOLESTEROL; DOWN-REGULATION; ENZYME REPRESSION; FIBROBLASTS; HAZARDOUS SUBSTANCES; HUMANS; ORGANOMETALLIC COMPOUNDS; POLYMERASE CHAIN REACTION; PROTEOMICS; RNA, MESSENGER; SELENOPROTEINS; SKIN; TANDEM MASS SPECTROMETRY;

EID: 84897945528     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2014.02.020     Document Type: Article

References (45)

1. Aebersold R., Mann M. Mass spectrometry-based proteomics. Nature 2003, 422:198-207.
2. ATSDR Toxicological profile for arsenic 2007, U.S. Department of Health and Human Services, Atlanta, GA.
3. Charoensuk V., Gati W.P., Weinfeld M., Le X.C. Differential cytotoxic effects of arsenic compounds in human acute promyelocytic leukemia cells. Toxicol. Appl. Pharmacol. 2009, 239:64-70.
4. Collotta M., Bertazzi P.A., Bollati V. Epigenetics and pesticides. Toxicology 2013, 307:35-41.
5. Cox J., Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 2008, 26:1367-1372.
6. Davis C.D., Tsuji P.A., Milner J.A. Selenoproteins and cancer prevention. Annu. Rev. Nutr. 2012, 32:73-95.
7. Defesche J.C. Low-density lipoprotein receptor-its structure, function, and mutations. Semin. Vasc. Med. 2004, 4:5-11.
8. Dong X., Xiong L., Jiang X., Wang Y. Quantitative proteomic analysis reveals the perturbation of multiple cellular pathways in Jurkat-T cells induced by doxorubicin. J. Proteome Res. 2010, 9:5943-5951.
9. Dong X., Xiao Y., Jiang X., Wang Y. Quantitative proteomic analysis revealed lovastatin-induced perturbation of cellular pathways in HL-60 cells. J. Proteome Res. 2011, 10:5463-5471.
10. Espenshade P.J., Hughes A.L. Regulation of sterol synthesis in eukaryotes. Annu. Rev. Genet. 2007, 41:401-427.
11. Flora S.J. Arsenic-induced oxidative stress and its reversibility. Free Radic. Biol. Med. 2011, 51:257-281.
12. Ganyc D., Talbot S., Konate F., Jackson S., Schanen B., Cullen W., Self W.T. Impact of trivalent arsenicals on selenoprotein synthesis. Environ. Health Perspect. 2007, 115:346-353.
13. Greenbaum D., Colangelo C., Williams K., Gerstein M. Comparing protein abundance and mRNA expression levels on a genomic scale. Genome Biol. 2003, 4:117.
14. Guo L., Xiao Y., Wang Y. Hexavalent chromium-induced alteration of proteomic landscape in human skin fibroblast cells. J. Proteome Res. 2013, 12:3511-3518.
15. Kensler T.W., Wakabayashi N., Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu. Rev. Pharmacol. Toxicol. 2007, 47:89-116.
16. Kitchin K.T. Recent advances in arsenic carcinogenesis: modes of action, animal model systems, and methylated arsenic metabolites. Toxicol. Appl. Pharmacol. 2001, 172:249-261.
17. Kitchin K.T., Wallace K. The role of protein binding of trivalent arsenicals in arsenic carcinogenesis and toxicity. J. Inorg. Biochem. 2008, 102:532-539.
18. Lau A., Whitman S.A., Jaramillo M.C., Zhang D.D. Arsenic-mediated activation of the Nrf2-Keap1 antioxidant pathway. J. Biochem. Mol. Toxicol. 2013, 27:99-105.
19. Lau A., Zheng Y., Tao S., Wang H., Whitman S.A., White E., Zhang D.D. Arsenic inhibits autophagic flux, activating the Nrf2-Keap1 pathway in a p62-dependent manner. Mol. Cell. Biol. 2013, 33:2436-2446.
20. Le X.C., Lu X., Li X.-F. Arsenic speciation. Anal. Chem. 2004, 76:26 A-33 A.
21. Lin S., Cullen W.R., Thomas D.J. Methylarsenicals and arsinothiols are potent inhibitors of mouse liver thioredoxin reductase. Chem. Res. Toxicol. 1999, 12:924-930.
22. -δδCt method. Methods 2001, 25:402-408.
23. Mandal B.K., Suzuki K.T. Arsenic round the world: a review. Talanta 2002, 58:201-235.
24. Mann K.K., Padovani A.M.S., Guo Q., Colosimo A.L., Lee H.-Y., Kurie J.M., Miller W.H. Arsenic trioxide inhibits nuclear receptor function via SEK1/JNK-mediated RXRα phosphorylation. J. Clin. Invest. 2005, 115:2924-2933.
25. Marafante E., Vahter M., Envall J. The role of the methylation in the detoxication of arsenate in the rabbit. Chem. Biol. Interact. 1985, 56:225-238.
26. Martinez F., Eschegoyen S., Briones R., Cuellar A. Cholesterol increase in mitochondria: a new method of cholesterol incorporation. J. Lipid Res. 1988, 29:1005-1011.
27. Medeiros M., Zheng X., Novak P., Wnek S.M., Chyan V., Escudero-Lourdes C., Gandolfi A.J. Global gene expression changes in human urothelial cells exposed to low-level monomethylarsonous acid. Toxicology 2012, 291:102-112.
28. Meno S.R., Nelson R., Hintze K.J., Self W.T. Exposure to monomethylarsonous acid (MMA(III)) leads to altered selenoprotein synthesis in a primary human lung cell model. Toxicol. Appl. Pharmacol. 2009, 239:130-136.
29. Ong S.E., Blagoev B., Kratchmarova I., Kristensen D.B., Steen H., Pandey A., Mann M. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol. Cell. Proteomics 2002, 1:376-386.
30. Petrick J.S., Ayala-Fierro F., Cullen W.R., Carter D.E., Vasken Aposhian H. Monomethylarsonous acid (MMA(III)) is more toxic than arsenite in Chang human hepatocytes. Toxicol. Appl. Pharmacol. 2000, 163:203-207.
31. Petrick J.S., Jagadish B., Mash E.A., Aposhian H.V. Monomethylarsonous acid (MMA(III)) and arsenite: LD(50) in hamsters and in vitro inhibition of pyruvate dehydrogenase. Chem. Res. Toxicol. 2001, 14:651-656.
32. Reeves M.A., Bellinger F.P., Berry M.J. The neuroprotective functions of selenoprotein M and its role in cytosolic calcium regulation. Antioxid. Redox Signal. 2010, 12:809-818.
33. Repa J.J., Liang G., Ou J., Bashmakov Y., Lobaccaro J.M., Shimomura I., Shan B., Brown M.S., Goldstein J.L., Mangelsdorf D.J. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev. 2000, 14:2819-2830.
34. Salomonis N., Hanspers K., Zambon A., Vranizan K., Lawlor S., Dahlquist K., Doniger S., Stuart J., Conklin B., Pico A. GenMAPP 2: new features and resources for pathway analysis. BMC Bioinforma. 2007, 8:217.
35. Shen S., Lee J., Cullen W.R., Le X.C., Weinfeld M. Arsenite and its mono- and dimethylated trivalent metabolites enhance the formation of benzo[a]pyrene diol epoxide-DNA adducts in Xeroderma pigmentosum complementation group A cells. Chem. Res. Toxicol. 2009, 22:382-390.
36. Shen S., Li X.-F., Cullen W.R., Weinfeld M., Le X.C. Arsenic binding to proteins. Chem. Rev. 2013, 113:7769-7792.
37. Smith A.H., Hopenhayn-Rich C., Bates M.N., Goeden H.M., Hertz-Picciotto I., Duggan H.M., Wood R., Kosnett M.J., Smith M.T. Cancer risks from arsenic in drinking water. Environ. Health Perspect. 1992, 97:259-267.
38. Takemoto M., Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler. Thromb. Vasc. Biol. 2001, 21:1712-1719.
39. Wang X.J., Sun Z., Chen W., Eblin K.E., Gandolfi J.A., Zhang D.D. Nrf2 protects human bladder urothelial cells from arsenite and monomethylarsonous acid toxicity. Toxicol. Appl. Pharmacol. 2007, 225:206-213.
40. Wang X.J., Sun Z., Chen W., Li Y., Villeneuve N.F., Zhang D.D. Activation of Nrf2 by arsenite and monomethylarsonous acid is independent of Keap1-C151: enhanced Keap1-Cul3 interaction. Toxicol. Appl. Pharmacol. 2008, 230:383-389.
41. Watanabe T., Hirano S. Metabolism of arsenic and its toxicological relevance. Arch. Toxicol. 2013, 87:969-979.
42. Wisniewski J.R., Zougman A., Nagaraj N., Mann M. Universal sample preparation method for proteome analysis. Nat. Methods 2009, 6:359-362.
43. Yousuf A.K., Misbahuddin M., Rahman M.S. Secretion of arsenic, cholesterol, vitamin E, and zinc from the site of arsenical melanosis and leucomelanosis in skin. Clin. Toxicol. 2011, 49:374-378.
44. Zhang F., Dai X., Wang Y. 5-Aza-2'-deoxycytidine induced growth inhibition of leukemia cells through modulating endogenous cholesterol biosynthesis. Mol. Cell. Proteomics 2012, 11. (M111 016915).
45. Zhu Y., Casey P.J., Kumar A.P., Pervaiz S. Deciphering the signaling networks underlying simvastatin-induced apoptosis in human cancer cells: evidence for non-canonical activation of RhoA and Rac1 GTPases. Cell Death Dis. 2013, 4:e568.